AKCEA THERAPEUTICS INC's ticker is AKCA and the CUSIP is 00972L107. A total of 63 filers reported holding AKCEA THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.26 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $103,703,000 | -28.7% | 5,716,836 | -46.1% | 0.01% | -37.5% |
| Q2 2020 | $145,379,000 | -5.0% | 10,611,618 | -0.8% | 0.02% | -23.8% |
| Q1 2020 | $152,969,000 | -16.4% | 10,697,119 | -0.9% | 0.02% | +5.0% |
| Q4 2019 | $182,886,000 | +4.8% | 10,796,140 | -4.8% | 0.02% | -4.8% |
| Q3 2019 | $174,527,000 | -39.2% | 11,340,286 | -7.3% | 0.02% | -38.2% |
| Q2 2019 | $287,016,000 | -22.4% | 12,239,489 | -6.2% | 0.03% | -22.7% |
| Q1 2019 | $369,794,000 | -8.3% | 13,053,064 | -2.5% | 0.04% | -20.0% |
| Q4 2018 | $403,318,000 | -10.4% | 13,381,506 | +4.1% | 0.06% | +7.8% |
| Q3 2018 | $450,275,000 | +52.5% | 12,857,672 | +3.2% | 0.05% | +50.0% |
| Q2 2018 | $295,317,000 | +15.2% | 12,455,383 | +24.5% | 0.03% | +13.3% |
| Q1 2018 | $256,306,000 | +47.9% | 10,008,016 | +0.3% | 0.03% | +50.0% |
| Q4 2017 | $173,274,000 | -28.6% | 9,981,244 | +13.8% | 0.02% | -31.0% |
| Q3 2017 | $242,626,000 | – | 8,768,569 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iguana Healthcare Management, LLC | 100,000 | $1,736,000 | 1.13% |
| BB BIOTECH AG | 1,248,650 | $21,677,000 | 0.61% |
| Virtus ETF Advisers LLC | 18,071 | $314,000 | 0.39% |
| Eventide Asset Management | 420,000 | $7,291,000 | 0.38% |
| Granahan Investment Management | 194,376 | $3,374,000 | 0.26% |
| ALTRINSIC GLOBAL ADVISORS LLC | 150,000 | $2,604,000 | 0.10% |
| Candriam S.C.A. | 114,571 | $1,990,000 | 0.03% |
| ARDSLEY ADVISORY PARTNERS LP | 15,000 | $260,000 | 0.03% |
| Delpha Capital Management, LLC | 1,521 | $26,000 | 0.03% |
| FMR LLC | 9,981,244 | $173,274,000 | 0.02% |